Autopsy report · NCT05360264

tailOred dRug repurposIng of dEcitabine in KRAS-dependeNt refracTory pAncreaTic cancEr

“Unexpected toxicity events were documented during interim safety evaluations of the investigational drug.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 3 months after it had already started.
• Ran for about 2 years 9 months before it stopped.
• 7 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Luca Cardone

Sponsor type

University, hospital or other

Conditions

Pancreatic Adenocarcinoma Metastatic; Pancreatic Adenocarcinoma Recurrent

Interventions

Decitabine 50 MG [Dacogen]

Participants

7

Sites

6

Countries

Italy

Trials that died the same way

• Pre-Prostatectomy Celecoxib or Placebo
  “Drug safety concerns” (64% match in meaning)
• GSK2983559 First Time in Human Study
  “Terminated due to non clinical toxicology findings and reduced safety margins.” (62% match in meaning)
• A Phase 2b Study to Evaluate RIST4721 in Palmoplantar Pustulosis (PPP)
  “Due to safety findings in ongoing Phase 2 trials.” (61% match in meaning)
• Safety and Efficacy Evaluation of Bosutinib Plus Atezolizumab in Newly Diagnosed Chronic Leukemia Adult Patients
  “The study has been prematurely terminated due to the onset of 2 dose limiting toxicities in 2 patients.” (60% match in meaning)
• A Dose Escalation Trial of PR610 Treating Patients With Solid Tumors
  “Study was prematurely discontinued due to unacceptable toxicity.” (60% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.